Tracking Big Pharma's Appetite For Regional Deals
This article was originally published in Start Up
Executive Summary
A review of Big Pharma regional dealmaking in 2006-2010 shows a slower uptick in the number of alliances than the steady year-over-year growth seen from 2001-2006.
You may also be interested in...
Valuing Infectious Disease Deals: EBI's new Deal Valuation Tool
The growing problem of antibiotic resistance has forced big drug companies to take renewed interest in novel anti-infectives. Although the number of deals signed thus far in 2011 in this therapeutic area is lower than in prior years, licensing commitments have remained strong. Different deal structure scenarios based on the recent platform alliance between Sanofi and Rib-X are taken through EBI's new Strategic Transactions Deal Valuation Tool.
Valuing Infectious Disease Deals: EBI's new Deal Valuation Tool
The growing problem of antibiotic resistance has forced big drug companies to take renewed interest in novel anti-infectives. Although the number of deals signed thus far in 2011 in this therapeutic area is lower than in prior years, licensing commitments have remained strong. Different deal structure scenarios based on the recent platform alliance between Sanofi and Rib-X are taken through EBI's new Strategic Transactions Deal Valuation Tool.
Valuing Infectious Disease Deals: EBI's new Deal Valuation Tool
The growing problem of antibiotic resistance has forced big drug companies to take renewed interest in novel anti-infectives. Although the number of deals signed thus far in 2011 in this therapeutic area is lower than in prior years, licensing commitments have remained strong. Different deal structure scenarios based on the recent platform alliance between Sanofi and Rib-X are taken through EBI's new Strategic Transactions Deal Valuation Tool.